An In Ovo Model for Testing Insulin-mimetic Compounds

Area of Science:

• Biomedical Science
• Pharmacology
• Endocrinology

Background:

• Type 2 diabetes mellitus (T2DM) is a complex metabolic disease characterized by insulin resistance and beta-cell dysfunction, leading to hyperglycemia.
• Current T2DM treatments include insulin therapy and insulin-sensitizing drugs, but interest in herbal compounds with insulin-mimetic potential is growing.
• Efficient screening systems are crucial for identifying and characterizing novel insulin-mimetic compounds from natural sources.

Purpose of the Study:

• To develop and validate a modified chick embryo model for testing insulin-mimetic compounds.
• To identify herbal extracts with the ability to enhance glucose uptake in adipocytes.
• To assess the in-ovo blood glucose-lowering efficacy of identified compounds.

Main Methods:

• A fluorescence microscopy-based primary screen was employed to quantify Glucose transporter 4 (Glut4) translocation to the plasma membrane in adipocytes.
• The chick embryo model was utilized for an in-ovo approach to evaluate the blood glucose-reducing properties of candidate compounds.
• Ethical considerations were addressed, as chicken embryos in the first two-thirds of development are not subject to animal experimentation regulations.

Main Results:

• The primary screen successfully identified compounds, predominantly herbal extracts, that increase intracellular glucose concentrations in adipocytes by promoting Glut4 translocation.
• The in-ovo model demonstrated the potential to verify the blood glucose-lowering efficacy of these identified substances in a living organism.
• The study details the application of this chick embryo model for compound screening.

Conclusions:

• The developed chick embryo model offers an efficient and ethically compliant system for screening compounds with insulin-mimetic activity.
• This model facilitates the identification of potential therapeutic agents for T2DM from both synthetic and herbal sources.
• Further validation in this in-ovo system is essential for confirming the efficacy of identified insulin-mimetic compounds before clinical application.